← Back to Search

Clinical Decision Support for Blood Transfusion Guidelines in Anemia

N/A

Recruiting

Led By Ryan Metcalf, MD

Research Sponsored by University of Utah

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up through study completion, an average of 12 months

Awards & highlights

No Placebo-Only Group

Summary

This trial will study if an alert system improves doctor's adherence to transfusion guidelines for 4 blood components. Both groups have access to info, but only one group will get alerts.

Who is the study for?

This trial is for healthcare providers who have the authority to order at least one type of blood product in an electronic health record system. It's not open to individuals without privileges to place initial orders for blood products.

What is being tested?

The study tests if a 'clinical decision support' alert improves adherence to transfusion guidelines when ordering red cells, plasma, platelets, and cryoprecipitate. Providers are randomly assigned to either see these alerts or not while both groups continue receiving education on best practices.

What are the potential side effects?

Since this trial involves a software tool rather than a medical treatment, traditional side effects aren't expected. However, there may be indirect effects on patient care depending on how the alerts influence provider behavior.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ through study completion, an average of 12 months

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~through study completion, an average of 12 months

This trial's timeline: 3 weeks for screening, Varies for treatment, and through study completion, an average of 12 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

Number of blood components transfused that met clinical decision support alert criteria

Secondary study objectives

Number of cryoprecipitate component pools transfused that met clinical decision support alert criteria

Number of plasma components transfused that met clinical decision support alert criteria

Number of platelet components transfused that met clinical decision support alert criteria

+1 more

Other study objectives

Blood component cost difference between clinical decision support eligible transfusions by study arm

Number of blood components ordered that met clinical decision support alert criteria

Number of blood components transfused

+8 more

Awards & Highlights

No Placebo-Only Group

All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups

Experimental Treatment

Active Control

Group I: Ordering Providers Assigned to Visible Clinical Decision Support AlertsExperimental Treatment1 Intervention

Clinical decision support alert will fire and become visible to the ordering provider in the electronic health record if blood product(s) are ordered out of accordance with guidelines. Information about transfusion guidelines and best practices will be sent to providers prior to starting the study and will be available on an internal website.

Group II: Ordering Providers Assigned to No Visible Clinical Decision Support AlertsActive Control1 Intervention

Clinical decision support alert will not be visible to the ordering provider in the electronic health record if blood product(s) are ordered out of accordance with guidelines. Information about transfusion guidelines and best practices will be sent to providers prior to starting the study and will be available on an internal website.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Clinical Decision Support

2019

N/A

~37100

Do I qualify?Apply below to find out